In relation to Anninga et al.: Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas

European Journal of Cancer

Volumn 40, Issue 7, 2004, Pages 924-925

  Judson, Ian ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; GEFITINIB; IMATINIB; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; LUNG SMALL CELL CANCER; ONCOGENE NEU; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

BONE NEOPLASMS; GENE EXPRESSION; GENES, ERBB-2; HUMANS; OSTEOSARCOMA;

EID: 1942485875     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.02.001     Document Type: Editorial

References (18)

1. Bilous M., Dowsett M., Hanna W.et al. Current perspectives on HER2 testing. a review of national testing guidelines Mod. Pathol. 16:2003;173-182.
2. Gorlick R., Huvos A.G., Heller G.et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. 17:1999;2781-2788.
3. Fletcher C.D.M., Berman J.J., Corless C.et al. Diagnosis of gastrointestinal stromal tumors. a consensus approach Hum. Pathol. 33:2002;459-465.
4. Verweij J., van Oosterom A., Blay J.Y.et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer. 39:2003;1976-1977.
5. Hirota S., Isozaki K., Moriyama Y.et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580.
6. Heinrich M.C., Corless C.L., Demetri G.D.et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21:2003;4342-4349.
7. Heinrich M.C., Corless C.L., Duensing A.et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710.
8. Johnson B.E., Fischer T., Fischer B.et al. Phase II study of imatinib in patients with small cell lung cancer. Clin. Cancer Res. 9:2003;5880-5887.
9. Johnson D.H. Gefitinib (Iressa) trials in non-small cell lung cancer. Lung Cancer. 41(Suppl. 1):2003;S23-S28.
10. Suzuki T., Nakagawa T., Endo H.et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer. 42:2003;35-41.
11. Albanell J., Rojo F., Averbuch S.et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients. histopathologic and molecular consequences of receptor inhibition J. Clin. Oncol. 20:2002;110-124.
12. Kris M., Natale R.B., Herbst R.S.et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. a randomised trial JAMA. 290:2003;2149-2158.
13. Zhou H., Randall R.L., Brothman A.R.et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J. Pediatr. Hematol. Oncol. 25:2003;27-32.
14. Maitra A., Wanzer D., Weinberg A.G., Ashfaq R. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer. 92:2001;677-683.
15. Thomas D.G., Giordano T.J., Sanders D., Biermann J.S., Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin. Cancer Res. 8:2002;788-793.
16. Bayani J., Zielenska M., Pandita A.et al. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer. 36:2003;7-16.
17. Kallioniemi O.-P., Kallioniemi A., Kurisu W.et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridisation. Proc. Natl. Acad. Sci. 89:1992;5321-5325.
18. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004, this issue (doi:10.1016/j.ejca.2003.10.025).